a BMI of 30 or higher qualifies only alongside heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or above
Across lifestyle blogs, expert-curated YouTube reviews, and comparison websites, the recurring themes include praise for the platform's ease of use, professional oversight, and real-world integration - particularly among busy professionals, parents, and aging adults who value convenience without compromising quality
While large-scale human trials remain limited, the existing research paints a promising picture
Costanza Alciati, Pharma Analyst, GlobalData, commented, Weight regain and reversal of cardiometabolic improvements are a huge limitation for all marketed GLP-1R agonists, not only for Zepbound. Results from the STEP 1 trial extension study investigating changes in body weight and cardiometabolic risk factors upon semaglutide treatment withdrawal show that upon treatment withdrawal at week 68, patients regained 11.6 per cent of body weight by week 120
Exenatide (Byetta) was the first GLP-1R agonist to be prescribed for the treatment of T2DM and is a synthetic analog of the GLP-1R agonist, Ex-4
